Ymmunobio AG is a preclinical stage biotechnology company developing two first in class assets in GI cancer.
Products, services, technology
YB-800, an ADC candidate with a new target receptor
YB-200, an immune agonist targeting CEACAM1 (orphan drug designation in HCC granted by FDA in Feb 2023)
Open to collaboration with companies who specialize in ADCs
GI cancers in figures:
1 in 2 cancers is a GI cancer
1 in 2 deaths are related to GI cancers
Ymmunobio develops new therapies for GI cancer patients to fill the current gaps in available therapy.
Great Team, Great Compounds, Great Partners, Great Investors.
James Allison, Tasuku Honjo, Katalin Kariko, Drew Weissman and more...
Because without groundbreaking discoveries there will be no progress in healing patients.
Teamwork, Listening, Entrepreneurial, Decades of Experience in Drug Development, Relationships within the Industry.
In the future we will need a colleague with CMC background and a CMO for sure.